In collaboration with the Institute of Systems Biology and the University of California, Los Angeles, Cellzome has mined its proteomic database to systematically investigate the physico-chemical principles governing mass spectrometric peptide sequencing.
Having generated this information, the team then developed software that enabled the genome wide prediction of so-called ‘proteotypic peptides’.
The use of proteotypic peptides can provide an approach to protein identification and to absolute protein quantification. This approach can therefore turn proteomics from a discovery tool into a quantitative biological science.
Tim Edwards, CEO of Cellzome, said: “This publication demonstrates once again the high scientific standard of our core research team. It illustrates one of the many ways in which we are exploiting our massive proteomic database: for the continuous improvement of our technology, for the benefit of our proprietary drug discovery projects, and for the benefit of our collaborations with leading pharmaceutical companies.”